1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.

Publisher Website
Google Scholar
Abstract
Three children with azotemic renal osteodystrophy were treated with 1,25-dihydroxycholecalciferol (1,25(OH)2D3). All showed clinical, biochemical and radiological improvement within 6 mo. of starting treatment. There were no complications. The dose of 1,25(OH)2D3 required was 0.5 .mu.g/day for 2 children aged 22 and 30 mo. and 2 .mu.g/day for a 15 yr old boy. Two of the patients were receiving phenobarbitone and phenytoin and in 1 of them prior treatment with dihydrotachysterol 0.5 mg/day and 6 .mu.g 1.alpha.-hydroxycholecalciferol (1.alpha.OHD3) daily had failed to induce improvement. In 1 patient in whom serial iliac bone samples were available 2 .mu.g 1,25(OH)2D3 resulted in histological improvement in previously severe osteomalacia. Apparently 1,25(OH)2D3 is an effective and safe drug in the treatment of uremic osteodystrophy.